{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.45","upperLimit":"9.55","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Progression-free survival is the defined as the time from study entry to disease progression (PD) or death based on Kaplan-Meier estimates. Patients alibe without PD are censored at the date of last disease evaluation. PD is defined as a greater than 25% increase in serum IgM monoclonal protein levels from the lowest attained response value as determined by serum electrophoresis, confirmed by at least one other investigation, or progression of clinically significant disease related symptom(s). \\[Consensus panel criteria: Weber et al, 2003; Kimby et al, 2005\\].","dispersionType":"95% Confidence Interval","groups":[{"description":"Simvastatin at 20 mg daily for the first week, then dose escalated weekly by 20 mg a day to a maximum of 80 mg daily by week 4. Patients were maintained on therapy until progression or up to 2 years.","id":"OG000","title":"Simvastatin"}],"paramType":"MEDIAN","populationDescription":"The analysis dataset is comprised of all evaluable patients. One patient was lost to follow-up within 3 weeks of enrollment and was unevaluable.","reportingStatus":"POSTED","timeFrame":"Assessed at month 1 and 3 and thereafter every 3 months while on therapy; Assessed every 6 months for up to 2 years of follow-up. Median follow-up in this study cohort was 6 months (range 2-18 months).","title":"Progression-Free Survival","type":"PRIMARY","unitOfMeasure":"months"}